Cite
HARVARD Citation
Albanell, J. et al. (2022). Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER). European journal of cancer. pp. 26-37. [Online].